Casma Therapeutics

Built on deep expertise in cellular degradation biology, Casma Therapeutics is advancing targeted therapies that engage the lysosomal or autophagy systems to selectively degrade disease targets and halt or reverse disease progression in neurodegeneration, oncology, inflammation, and metabolic disorders. Casma’s first-in-class TRPML1 agonist restores lysosomal function to treat Gaucher's disease patients with Parkinson's disease, and is poised to expand into GBA-associated Parkinson’s disease and idiopathic Parkinson’s disease. Casma’s PHLYTTM degrader platform is unlocking new therapeutic possibilities through selective autophagy-targeted degradation of large, complex disease targets such as organelles, protein aggregates, and signaling complexes.